Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).
Credit: Sha, T.T., et al
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).
Invasive liver biopsy continues to be the gold standard for diagnosing NASH through the histopathological assessment of liver steatosis, ballooning and lobular inflammation. However, this method does have its limitations, including sampling bias, low patient acceptance and potential complications. Clinical imaging techniques such as ultrasound and magnetic resonance imaging can detect or quantify liver steatosis, but are unable to differentiate between NASH and NAFLD. Therefore, there is a need to identify noninvasive parameters associated with NASH that can serve as surrogate markers for these histologic features.
In a study published in the KeAi journal Liver Research, a group of Chinese researchers detailed a sequential ultrasound molecular imaging (USMI), an emerging strategy for the identification of NASH by visualizing hepatic steatosis and inflammation. Notably, distinct microbubbles (MBs) were used to target CD36 and ICAM-1 individually, rather than a dual-targeted MB. This approach allows for the differentiation of the signal source (either steatosis or inflammation) and the identification of the predominant pathological change.
“As a noninvasive diagnostic tool, this strategy has the potential to assist in clinical therapeutic decision-making and contribute to drug development for NASH,” says Tinghui Yin, lead author of the study. “Furthermore, among various sequential USMI-based diagnostic models, the serial testing model showed high diagnostic performance in detecting NASH, with 95% sensitivity, 97% specificity, 95% positive predictive values, 97% negative predictive values and 96% accuracy.”
CD36 is known to be associated with liver steatosis, while elevated ICAM-1 levels are seen in the progression of liver inflammation. Hence, quantitatively visualizing hepatic CD36 and ICAM-1 can provide valuable information in determining the extent of hepatic steatosis and inflammation. This achievement brings researchers one step closer to the ultimate objective of establishing a viable noninvasive approach for detecting NASH.
###
Contact the author: Tinghui Yin, Department of Medical Ultrasound, Laboratory of Novel Optoacoustic (Ultrasonic) Imaging, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. E-mail address: [email protected].
The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 100 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).
Journal
Liver Research
DOI
10.1016/j.livres.2023.11.002
Method of Research
Experimental study
Subject of Research
Animals
Article Title
Sequential ultrasound molecular imaging for noninvasive identification and assessment of non-alcoholic steatohepatitis in mouse models
COI Statement
Rongqin Zheng is an editorial board member for Liver Research and was not involved in the editorial review or the decision to publish this article.The authors declare that there is no conflicts of interest. Please paste here the Declaration of Competing Interest statement from your published article.